Q2 Earnings Round-Up Part 1: Signs Of Pandemic Recovery
Executive Summary
Small-to-medium-sized companies launching their first or one of their only commercial products faced a particular difficult time during the pandemic. In the second quarter earnings calls, some of these SMEs are seeing momentum as the most serious COVID headwinds resolve but others are contending with ongoing challenges. [Check back tomorrow for Part 2 on companies experiencing continuing challenges.]
You may also be interested in...
Trials In Focus: Diverse Enrollment Lagging In Oncology, IQVIA Finds
Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.
Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain
The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.
ASCO Preview: Five Top Late-Breakers To Watch For
AstraZeneca plans to unveil multiple major data packages, while Servier reveals much-anticipated results in glioma, and ImmunoGen and Novartis will present key pivotal data in women’s cancers.